IN2014DN08443A - - Google Patents

Info

Publication number
IN2014DN08443A
IN2014DN08443A IN8443DEN2014A IN2014DN08443A IN 2014DN08443 A IN2014DN08443 A IN 2014DN08443A IN 8443DEN2014 A IN8443DEN2014 A IN 8443DEN2014A IN 2014DN08443 A IN2014DN08443 A IN 2014DN08443A
Authority
IN
India
Prior art keywords
compounds
pentifylline
derivatives
relates
novel
Prior art date
Application number
Other languages
English (en)
Inventor
Roger D Tung
Bhaumik Pandya
Scott L Harbeson
Original Assignee
Concert Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concert Pharmaceuticals Inc filed Critical Concert Pharmaceuticals Inc
Publication of IN2014DN08443A publication Critical patent/IN2014DN08443A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/10—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 3 and 7, e.g. theobromine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN8443DEN2014 2012-04-13 2013-04-12 IN2014DN08443A (pm)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261623858P 2012-04-13 2012-04-13
PCT/US2013/036454 WO2013155465A1 (en) 2012-04-13 2013-04-12 Substituted xanthine derivatives

Publications (1)

Publication Number Publication Date
IN2014DN08443A true IN2014DN08443A (pm) 2015-05-08

Family

ID=48184515

Family Applications (1)

Application Number Title Priority Date Filing Date
IN8443DEN2014 IN2014DN08443A (pm) 2012-04-13 2013-04-12

Country Status (11)

Country Link
US (1) US9328113B2 (pm)
EP (1) EP2836492B1 (pm)
JP (1) JP2015512947A (pm)
KR (1) KR20150002779A (pm)
CN (1) CN104364255A (pm)
AU (1) AU2013245662A1 (pm)
CA (1) CA2869874A1 (pm)
EA (1) EA201491878A8 (pm)
IN (1) IN2014DN08443A (pm)
MX (1) MX2014012384A (pm)
WO (1) WO2013155465A1 (pm)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263601B2 (en) 2009-02-27 2012-09-11 Concert Pharmaceuticals, Inc. Deuterium substituted xanthine derivatives
EP3377179B1 (en) 2015-11-19 2021-04-07 Concert Pharmaceuticals Inc. Deuterated epi-743
US11731947B2 (en) 2019-04-10 2023-08-22 University Of Notre Dame Du Lac Deuterated antimicrobial compounds
WO2022056190A2 (en) * 2020-09-14 2022-03-17 Lennham Pharmaceuticals, Inc. Deuterated paraxanthine and uses thereof
US12194046B2 (en) 2021-03-09 2025-01-14 Lennham Pharmaceuticals, Inc. D9-caffeine compositions and uses thereof

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE860217C (de) 1950-10-28 1952-12-18 Albert Ag Chem Werke Verfahren zur Herstellung von 1-Hexyl-3, 7-dimethylxanthin
JPS5576876A (en) 1978-12-05 1980-06-10 Grelan Pharmaceut Co Ltd Preparation of 1-(oxoalkyl)-3,7-dimethylxanthine derivatne
JPS55122779A (en) 1979-03-13 1980-09-20 Maruko Seiyaku Kk Preparation of theobromine derivative
CS201558B1 (en) 1979-05-14 1980-11-28 Pavol Kovar Method of preparing 1-/5-oxohexyl/-3,7-dimethylxanthine
JPS567785A (en) 1979-07-02 1981-01-27 Maruko Seiyaku Kk Preparation of theobromine derivative
JPS5610187A (en) 1979-07-05 1981-02-02 Grelan Pharmaceut Co Ltd Separation and purification of 1-(5-oxohexyl)- 3,7-dimethylxanthine
JPS5610188A (en) 1979-07-06 1981-02-02 Dainippon Ink & Chem Inc Xanthine derivative and its preparation
JPS5632477A (en) 1979-08-27 1981-04-01 Nippon Iyakuhin Kaihatsu Kenkyusho:Kk Preparation of 1- 5-oxohexyl -3,7-dimethylxanthine
JPS5677279A (en) 1979-11-28 1981-06-25 Ota Seiyaku Kk Preparation of xanthine derivative
JPS5711981A (en) 1980-06-26 1982-01-21 Sagami Chem Res Center Theobromine derivative and its preparation
JPS5724382A (en) 1980-07-17 1982-02-08 Nissan Chem Ind Ltd Trithiane derivative and its preparation
JPS5724386A (en) 1980-07-17 1982-02-08 Nissan Chem Ind Ltd Preparation of xanthine derivative
JPS5724385A (en) 1980-07-17 1982-02-08 Nissan Chem Ind Ltd Theobromine derivative and its preparation
JPS5756481A (en) 1980-09-22 1982-04-05 Kawashima Yakuhin Kaihatsu Kk Production of 1-(5-oxohexyl)-3,7-dimethylxanthine
JPS5762278A (en) 1980-10-01 1982-04-15 Sagami Chem Res Center Theobromine derivative and its preparation
JPS5780385A (en) 1980-11-05 1982-05-19 Mitsubishi Petrochem Co Ltd Preparation of 1-((omega-1)-oxoalkyl)-3,7-dialkylxanthine
JPS5785387A (en) 1980-11-14 1982-05-28 Teikoku Chem Ind Corp Ltd Preparation of 1-(-5'-oxohexyl)-3,7-dimethylxanthine
JPS5798284A (en) 1980-12-10 1982-06-18 Kawashima Yakuhin Kaihatsu Kk Preparation of 1-(5-oxohexyl)-3,7-dimethylxanthine
JPS57200391A (en) 1981-06-02 1982-12-08 Daito Koeki Kk 1-(5-oxo-2-hexenyl)3,7-dimethylxanthine
JPS5838284A (ja) 1981-09-01 1983-03-05 Teikoku Chem Ind Corp Ltd １−（５′−オキソヘキシル）−３，７−ジメチルキサンチンの製造方法
JPS58134092A (ja) 1982-02-05 1983-08-10 Sagami Chem Res Center テオブロミン誘導体
JPS58150594A (ja) 1982-03-03 1983-09-07 Daito Koeki Kk キサンチン誘導体の製造方法
CS237719B1 (cs) 1983-05-12 1985-10-16 Jan Jendrichovsky SpAsob přípravy dimetyl-(5-oxohexyl)-xantlnov
DE3508097A1 (de) 1984-07-21 1986-02-06 Hoechst Ag, 6230 Frankfurt Kombinationspraeparat aus xanthinderivaten und o-acetylsalicylsaeure bzw. deren pharmakologisch vertraeglichen salzen und dessen verwendung
DE3525801A1 (de) 1985-07-19 1987-01-22 Hoechst Ag Tertiaere hydroxyalkylxanthine, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung
DD274334A3 (de) 1985-12-17 1989-12-20 Dresden Arzneimittel Verfahren zur herstellung von reinem 3,7-dimethyl-1-(5-oxohexyl)-xanthin
IL106854A (en) 1986-12-31 1996-05-14 Hoechst Roussel Pharma Pantoxifilin metabolites and pharmaceutical preparations containing them to prevent an immune reaction and to reduce undesirable conditions in this regard
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5112827A (en) 1990-05-18 1992-05-12 Board Of Regents, The University Of Texas System Drug to reverse fatty liver and atheromatous lesions
AU9084991A (en) 1990-11-01 1992-05-26 Board Of Regents, The University Of Texas System Antifungal activity of and prevention of drug induced nephrotoxicity by methylxanthine analogues
EP0484785B1 (en) 1990-11-07 1996-05-22 Hoechst-Roussel Pharmaceuticals Incorporated Use of xanthines for the preparation of a medicament effective for inhibiting the replication of human retroviruses
EP0490181A1 (en) 1990-11-30 1992-06-17 Hoechst-Roussel Pharmaceuticals Incorporated Use of xanthines for preparation of a medicament having immunosuppressing activity
EP0493682A3 (en) 1990-11-30 1992-11-19 Hoechst-Roussel Pharmaceuticals Incorporated Use of xanthines for the preparation of a medicament effective for inhibiting the effects of allograft reaction in humans
US6420374B1 (en) 1990-11-30 2002-07-16 Fred Hutchinson Cancer Research Center Use of xanthines as immunosuppressants and to inhibit allograft reactions
US5648357A (en) 1992-03-04 1997-07-15 Cell Therapeutics, Inc. Enatiomerically pure hydroxylated xanthine compounds
US5763446A (en) 1992-03-26 1998-06-09 University Of Southern California Use of pentoxifylline and other tumor necrosis factor blockers for the treatment of aids-associated optic neuropathy and other central nervous system diseases
US5804584A (en) 1992-11-16 1998-09-08 Cell Therapeutics, Inc. Therapeutic compounds containing a monocyclic five- to six- membered ring structure having one to two nitrogen atoms
US6020337A (en) 1993-04-05 2000-02-01 Cell Therapeutics, Inc. Electronegative-substituted long chain xanthine compounds
US5670506A (en) 1993-04-05 1997-09-23 Cell Therapeutics, Inc. Halogen, isothiocyanate or azide substituted xanthines
US5716981A (en) 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
HUT68560A (en) 1993-08-02 1995-04-27 Chinoin Gyogyszer Es Vegyeszet The use of xantine derivatives for promotion of healing of operative lesions
ATE372966T1 (de) 1994-03-25 2007-09-15 Isotechnika Inc Verbesserung der effektivität von arzneimitteln duren deuterierung
US6221335B1 (en) 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
EP0759915B1 (en) 1994-05-16 2002-10-16 Cell Therapeutics, Inc. Asymmetric synthesis of chiral secondary alcohols
DE4430128A1 (de) 1994-08-25 1996-02-29 Hoechst Ag Kombinationspräparat mit immunsuppressiven, kardiovaskulären und cerebralen Wirkungen
AU3539795A (en) 1994-08-25 1996-03-14 Medical University Of South Carolina Methods of treating cold symptoms using pentoxifylline
DE4430127A1 (de) 1994-08-25 1996-03-14 Hoechst Ag Kombinationspräparat, enthaltend Cyclosporin A oder FK506 und ein Xanthinderivat
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
DE19544768C1 (de) 1995-11-30 1997-07-10 Rentschler Arzneimittel Verwendung einer Kombination aus Pentoxifyllin mit Typ-I-Interferonen zur Behandlung der Multiplen Sklerose
US6294350B1 (en) 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
US5985592A (en) 1997-06-05 1999-11-16 Dalhousie University Uses for pentoxifylline or functional derivatives/metabolites thereof
US6440710B1 (en) 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
US6316458B1 (en) 1999-04-30 2001-11-13 Cell Therapeutics, Inc. Method of enhancing insulin action
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
PT1104760E (pt) * 1999-12-03 2003-06-30 Pfizer Prod Inc Compostos de sulfamoil-heteroarilpirazole como agentes analgesicos e anti-inflamatorios
RS83503A (en) 2001-05-03 2006-10-27 F. Hoffmann-La Roche Ag. Pharmaceutical dosage form of amorphous nelfinavir mesylate
EP1392262A1 (en) 2001-05-24 2004-03-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
WO2003013568A1 (en) 2001-08-02 2003-02-20 Ortho-Mcneil Pharmaceutical, Inc. Cytokine modulation therapy
US20050107420A1 (en) 2002-05-23 2005-05-19 Boehringe Ingelheim Pharma Gmbh & Co. Kg Combination of a PDE4 inhibitor and tiotropium or derivative thereof for treating obstructive airways and other inflammatory diseases
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
WO2005023193A2 (en) 2003-09-04 2005-03-17 Interleukin Genetics, Inc. Methods of treating endometriosis
WO2006035417A2 (en) 2004-09-27 2006-04-06 Sigmoid Biotechnologies Limited Dihydropyrimidine microcapsule - formulations
BRPI0516170A (pt) 2004-09-29 2008-08-26 Cordis Corp formas de dosagens farmacêuticas estáveis e amorfas de compostos de rapamicina
BRPI0617987A2 (pt) 2005-10-06 2011-08-16 Auspex Pharmaceuticals Inc composição, composição farmacêutica, forma de dosagem efervescente, composição farmacêutica oral de comprimidos unitários múltiplos, forma de dosagem farmacêutica de liberação prolongada, forma de dosagem farmacêutica revestida entérica, forma de dosagem farmacêutica estável para administração oral a sujeitos mamìferos, método para tratamento de doenças relacionadas a ácido gástrico pela inibição de secreção de ácido gástrico, método para tratamento de uma infecção bacteriana provocada ou mediada por helicobacter pylori, processo para preparar um composto da fórmula 3, processo para preparar um composto da fórmula 5, uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de doenças relacionadas a ácido gástrico, pela inibição de secreção de ácido gástrico, uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de uma infecção bacteriana provocada ou mediada por helicobacter pylori uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de doenças relecionadas a ácido gástrico pela inibição de secreção de ácido gástrico
US7750168B2 (en) 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
JP2010502702A (ja) 2006-09-05 2010-01-28 シェーリング コーポレイション 脂質管理およびアテローム性動脈硬化症および脂肪肝の治療治療において使用される医薬組成物
BRPI0908107A2 (pt) 2008-02-29 2019-09-24 Concert Pharmaceuticals Inc composto derivado de xantina substituída, composição farmacêutica que compreende esse composto, métodos de tratamento de uma enfermidade ou condição em um paciente com necessidade do mesmo, método de tratamento de enfermidade crônica dos rins, do fígado, relacionada com diabetes e de claudicação intermitente
US20110053961A1 (en) 2009-02-27 2011-03-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
US8263601B2 (en) 2009-02-27 2012-09-11 Concert Pharmaceuticals, Inc. Deuterium substituted xanthine derivatives
AU2010289551A1 (en) 2009-09-02 2012-03-01 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives

Also Published As

Publication number Publication date
EA201491878A1 (ru) 2015-01-30
AU2013245662A1 (en) 2014-10-30
US20150119407A1 (en) 2015-04-30
US9328113B2 (en) 2016-05-03
CA2869874A1 (en) 2013-10-17
WO2013155465A1 (en) 2013-10-17
WO2013155465A8 (en) 2014-11-13
MX2014012384A (es) 2014-11-26
EP2836492A1 (en) 2015-02-18
KR20150002779A (ko) 2015-01-07
JP2015512947A (ja) 2015-04-30
CN104364255A (zh) 2015-02-18
EP2836492B1 (en) 2018-03-14
EA201491878A8 (ru) 2015-02-27

Similar Documents

Publication Publication Date Title
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
PH12017500941A1 (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
IN2015DN01156A (pm)
IN2012DN01641A (pm)
MX2015012502A (es) Inhibidores de proteina cinasa dependiente de adn.
MA39986A (fr) Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer
MY192717A (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
UA115983C2 (uk) Інгібітори днк-пк
PH12014502757B1 (en) Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
MD4820B1 (ro) Compuşi dihidroizochinolinonici substituiţi
IN2014DN10670A (pm)
MY177344A (en) Compounds and their methods of use
IN2015DN01151A (pm)
MX2015007916A (es) Peri-carbinoles.
PH12016502291A1 (en) Indolizine derivatives as phosphoinositide 3-kinases inhibitors
MY181602A (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors
IN2012DN01642A (pm)
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
PH12014501979B1 (en) Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
MX2014013758A (es) Derivados de tiazolcarboxamida para usarse como inhibidores de nampt.
IN2014DN08443A (pm)
UA117567C2 (uk) Композиція, яка стимулює лактацію, на основі фосфатидилсерину
MX2014009084A (es) Derivados de pirimidooxazocina como inhibidores de mtor.